KRRO
Korro Bio, Inc.
Key Financials
Revenue
$6.4M
↑ 181.5%
Operating Income
$-121855000
↓ 32.6%
Net Income
$-117260000
↓ 40.3%
Total Assets
$113.5M
↓ 49.8%
EPS (Diluted)
$-12.48
↓ 33.2%
Cash & Equivalents
$21.8M
↓ 60.8%
Total Liabilities
$62.1M
↓ 5.7%
Long-term Debt
$180000.00
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/19/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 424B3 | 5/12/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| ARS | 4/16/2026 | View on SEC |
| DEFA14A | 4/16/2026 | View on SEC |
| DEF 14A | 4/16/2026 | View on SEC |
| SCHEDULE 13G/A | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KRRO |
| Company Name | Korro Bio, Inc. |
| CIK | 1703647 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-468-1999 |